White Matter Hyperintensities Modify CYP2C19 Effect on Stroke Progression in Small Vessel Occlusion

BACKGROUND: The association between CYP2C19 loss-of-function (LOF) alleles and early neurological deterioration (END) in acute small vessel occlusion (SVO) patients receiving dual antiplatelet therapy (DAPT) remains inconsistent. We hypothesized that white matter hyperintensities (WMH) burden act as a key moderator and investigated whether this modulates the association between CYP2C19 LOF and END. METHODS: We conducted a retrospective study of SVO patients receiving DAPT. CYP2C19 genotypes were classified as LOF carriers or non-carriers. The primary endpoint was END; secondary and safety endpoints included severe END, 90-day mRS 0-2, symptomatic intracranial hemorrhage (sICH), bleeding, and mortality. Multivariable regression and interaction analyzes assessed associations between CYP2C19, WMH, and clinical outcomes. RESULTS: A total of 247 patients (median age 67.0 years; 28.7% female; 60.7% CYP2C19 LOF carriers), 54 (21.9%) experienced END. Multivariable analysis identified infarct diameter (aOR 1.26, 95% CI 1.13-1.39, p < 0.001) and total cerebral small vessel disease (CSVD) burden (aOR 2.02, 95% CI 1.37-2.98, p < 0.001) as independent predictors. A significant multiplicative interaction was observed between CYP2C19 LOF and severe WMH on END risk (aOR 9.34, 95% CI 2.06-48.10, p = 0.005). Stratified analysis showed CYP2C19 LOF significantly increased END risk specifically in patients with severe WMH (aOR 3.44, 95% CI 1.12-10.55, p = 0.030), but not mild WMH. Predicted probability curves suggested a Fazekas score threshold of approximately 2.70. Secondary and safety outcomes were infrequent. CONCLUSIONS: CYP2C19 LOF alleles increase END risk in SVO patients specifically with severe WMH. These findings highlight the value of integrating genetic and neuroimaging markers for risk stratification and personalized antiplatelet therapy.

Authors

Institutions

Publication Details

Journal
Annals of Clinical and Translational Neurology
Published
2026-11-13
DOI
https://doi.org/10.1002/acn3.70579
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

White Matter Hyperintensities Modify CYP2C19 Effect on Stroke Progression in Small Vessel Occlusion

Zhiyong Zhang, M Wang, Xiaoxin Sun, Xinxiu Liu et al.
Annals of Clinical and Translational Neurology
Acute Ischemic Stroke Management
article

White Matter Hyperintensities Modify CYP2C19 Effect on Stroke Progression in Small Vessel Occlusion

Zhiyong Zhang, M Wang, Xiaoxin Sun, Xinxiu Liu, Lei Wang, Rui Zhu
article en

Abstract

BACKGROUND: The association between CYP2C19 loss-of-function (LOF) alleles and early neurological deterioration (END) in acute small vessel occlusion (SVO) patients receiving dual antiplatelet therapy (DAPT) remains inconsistent. We hypothesized that white matter hyperintensities (WMH) burden act as a key moderator and investigated whether this modulates the association between CYP2C19 LOF and END. METHODS: We conducted a retrospective study of SVO patients receiving DAPT. CYP2C19 genotypes were classified as LOF carriers or non-carriers. The primary endpoint was END; secondary and safety endpoints included severe END, 90-day mRS 0-2, symptomatic intracranial hemorrhage (sICH), bleeding, and mortality. Multivariable regression and interaction analyzes assessed associations between CYP2C19, WMH, and clinical outcomes. RESULTS: A total of 247 patients (median age 67.0 years; 28.7% female; 60.7% CYP2C19 LOF carriers), 54 (21.9%) experienced END. Multivariable analysis identified infarct diameter (aOR 1.26, 95% CI 1.13-1.39, p < 0.001) and total cerebral small vessel disease (CSVD) burden (aOR 2.02, 95% CI 1.37-2.98, p < 0.001) as independent predictors. A significant multiplicative interaction was observed between CYP2C19 LOF and severe WMH on END risk (aOR 9.34, 95% CI 2.06-48.10, p = 0.005). Stratified analysis showed CYP2C19 LOF significantly increased END risk specifically in patients with severe WMH (aOR 3.44, 95% CI 1.12-10.55, p = 0.030), but not mild WMH. Predicted probability curves suggested a Fazekas score threshold of approximately 2.70. Secondary and safety outcomes were infrequent. CONCLUSIONS: CYP2C19 LOF alleles increase END risk in SVO patients specifically with severe WMH. These findings highlight the value of integrating genetic and neuroimaging markers for risk stratification and personalized antiplatelet therapy.

Annals of Clinical and Translational Neurology
Beijing Geriatric Hospital (CN)
Acute Ischemic Stroke Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon